Testing effectiveness (Phase 2)Ended earlyNCT03630809
What this trial is testing
Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1
Who this might be right for
Breast CancerHER2-positive Breast CancerHER-2 Gene Amplification+4 more
H. Lee Moffitt Cancer Center and Research Institute 16